Development of 225 Ac/ 213 Bi generator based on α-ZrP-PAN composite for targeted alpha therapy.

Autor: Ondrák L; Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 87/7, 115 19 Prague, Czech Republic. Electronic address: lukas.ondrak@fjfi.cvut.cz., Ondrák Fialová K; Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 87/7, 115 19 Prague, Czech Republic., Sakmár M; Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 87/7, 115 19 Prague, Czech Republic., Vlk M; Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 87/7, 115 19 Prague, Czech Republic., Bruchertseifer F; European Commission, Joint Research Centre, Karlsruhe, Germany., Morgenstern A; European Commission, Joint Research Centre, Karlsruhe, Germany., Kozempel J; Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 87/7, 115 19 Prague, Czech Republic.
Jazyk: angličtina
Zdroj: Nuclear medicine and biology [Nucl Med Biol] 2024 May-Jun; Vol. 132-133, pp. 108909. Date of Electronic Publication: 2024 Mar 28.
DOI: 10.1016/j.nucmedbio.2024.108909
Abstrakt: Background: Radioligand therapy using alpha emitters has gained more and more prominence in the last decade. Despite continued efforts to identify new appropriate radionuclides, the combination of 225 Ac/ 213 Bi remains among the most promising. Bismuth-213 has been employed in clinical trials in combination with appropriate vectors to treat patients with various forms of cancer, such as leukaemia, bladder cancer, neuroendocrine tumours, melanomas, gliomas, or lymphomas. However, the half-life of 213 Bi (T ½  = 46 min) implies that its availability for clinical use is limited to hospitals possessing a 225 Ac/ 213 Bi radionuclide generator, which is still predominantly scarce. We investigated a new Ac/Bi generator system based on using the composite sorbent α-ZrP-PAN (zirconium(IV) phosphate as active component and polyacrylonitrile as matrix). The developed 225 Ac/ 213 Bi generator was subjected to long-term testing after its development. The elution profile was determined and the elution yield, the contamination of the eluate with the parent 225 Ac and the contamination of the eluate with the column material were monitored over time.
Results: The high activity (75 MBq of parent 225 Ac) generator with a length of 75 mm and a diameter of 4 mm containing the composite sorbent α-ZrP-PAN with a particle size of 0.8 to 1.0 mm as the stationary phase, eluted with a mixture of 10 mM DTPA in 5 mM nitric acid, provided 213 Bi with yields ranging from 77 % to 96 % in 2.8 mL of eluate, with parent 225 Ac contamination in the order of 10 -3  %, up to twenty days of use.
Conclusion: All the results of the monitored parameters indicate that the composite sorbent α-ZrP-PAN based separation system for the elution of 213 Bi is a very promising and functional solution.
Competing Interests: Declaration of competing interest The authors declare that they have no competing interests.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: